Big Pharma Has Spent Nearly $150 Billion On M&A (So Far) In 2025 [Forbes]
Cidara Therapeutics, Inc. (CDTX)
Last cidara therapeutics, inc. earnings: 3/4 05:55 am
Check Earnings Report
US:NASDAQ Investor Relations:
ir.cidara.com
Company Research
Source: Forbes
subscribe here erck announced last week that it would acquire biotech Cidara Therapeutics for about $9.2 billion . The primary reason: Cidara's antiviral drug to prevent flu infections among patients with a high risk of complications, currently in late-stage clinical trials. The deal is Merck's second multi-billion dollar acquisition following its $10 billion agreement to buy Verona Pharma for its respiratory drugs in July. The Merck deals are just the latest sign of this year's biotech deal frenzy. This month alone has seen Pfizer's $10 billion acquisition of Metsera after a bidding war for its weight-loss drugs with Novo Nordisk and Johnson & Johnson's $3 billion agreement to buy Halda Therapeutics for its cancer therapies. The dollar volume of M&A (through October 31) hit $129 billion, 43% more than in all of 2024, according to accounting firm EY. Intriguingly, the industry hit that with just 67 deals–26% fewer deals than in 2024, because the average deal size in 2025, at $1
Show less
Read more
Impact Snapshot
Event Time:
CDTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CDTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CDTX alerts
High impacting Cidara Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
CDTX
News
- Halper Sadeh LLC Encourages GIFI, MOVE, RMBI, CDTX Shareholders to Contact the Firm to Discuss Their RightsPR Newswire
- Cidara Therapeutics Reaches Target Enrollment of Phase 3 ANCHOR Trial Evaluating CD388 for Prevention of Seasonal Influenza in High-Risk PopulationsGlobeNewswire
- SHAREHOLDER ALERT: The M&A Class Action Firm Continues to Investigate the Mergers-NUVSF, NDTAF, THS, and CDTXPR Newswire
- Cidara Therapeutics (NASDAQ:CDTX) had its "neutral" rating reaffirmed by analysts at Guggenheim.MarketBeat
- Is Cidara Therapeutics Fairly Priced After Its 110% Surge and New Clinical Milestones? [Yahoo! Finance]Yahoo! Finance
CDTX
Earnings
- 11/6/25 - Miss
CDTX
Sec Filings
- 12/5/25 - Form SC
- 12/5/25 - Form SC
- 11/17/25 - Form SCHEDULE
- CDTX's page on the SEC website